KAM
SCMP

Krensavage Asset Management’s Sucampo Pharmaceuticals, Inc. SCMP Stock Holding History

Krensavage Asset Management’s Portfolio SCMP Stock Details SCMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-1,304,376
Closed -$23.4M – 17
2017
Q4 		$23.4M Sell
1,304,376
-1,529,040
-54% -$18.8M 7.3% 5
2017
Q3 		$33.4M Buy
2,833,416
+13,708
+0.5% +$154K 10.42% 5
2017
Q2 		$29.6M Buy
2,819,708
+16,570
+0.6% +$169K 8.99% 5
2017
Q1 		$30.8M Buy
2,803,138
+939,383
+50% +$10.9M 9.94% 5
2016
Q4 		$25.3M Buy
1,863,755
+211,857
+13% +$2.96M 9.05% 4
2016
Q3 		$20.3M Buy
1,651,898
+20,500
+1% +$242K 7.35% 6
2016
Q2 		$17.9M Buy
1,631,398
+1,073,169
+192% +$12M 6.45% 8
2016
Q1 		$6.1M Buy
558,229
+2,577
+0.5% +$32.6K 2.19% 17
2015
Q4 		$9.61M Buy
555,652
+27,477
+5% +$493K 3.07% 13
2015
Q3 		$10.5M Sell
528,175
-439,229
-45% -$10.1M 3.8% 13
2015
Q2 		$15.9M Buy
967,404
+33,538
+4% +$582K 5.99% 7
2015
Q1 		$14.5M Sell
933,866
-24,182
-3% -$375K 6.62% 6
2014
Q4 		$13.7M Buy
+958,048
New +$10.1M 7.62% 3

Other funds holding SCMP

GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
AIM
Advantage Investment Management Cedar Rapids, Iowa $128M AUM 0.94% 1-Year Est. Return

Krensavage Asset Management's SCMP Position: Q1 2018 in Review

Krensavage Asset Management sold out of Sucampo Pharmaceuticals, Inc. (SCMP) in Q1 2018, closing a stake of 1,304,376 shares — an estimated $23.4M sold.

Krensavage Asset Management first reported a position in SCMP in Q4 2014 and held it in 13 quarters. The position peaked at $33.4M in Q3 2017. 3 funds tracked by Wall St. Rank hold SCMP as of Q1 2018.

  • Krensavage Asset Management reported no remaining Sucampo Pharmaceuticals, Inc. position as of Q1 2018 after selling out during the quarter.
  • Krensavage Asset Management sold 1,304,376 Sucampo Pharmaceuticals, Inc. shares in Q1 2018, an estimated $23.4M.
  • Krensavage Asset Management first reported a position in Sucampo Pharmaceuticals, Inc. in Q4 2014 and held it in 13 quarters.
  • Krensavage Asset Management's Sucampo Pharmaceuticals, Inc. position peaked at $33.4M in Q3 2017.
  • 3 funds tracked by Wall St. Rank held Sucampo Pharmaceuticals, Inc. as of Q1 2018.

Based on Krensavage Asset Management's 13F filing for Q1 2018, filed 14 May 2018.